T-62
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postherpetic Neuralgia
Conditions
Postherpetic Neuralgia
Trial Timeline
— → —
NCT ID
NCT00506610About T-62
T-62 is a phase 2 stage product being developed by Pfizer for Postherpetic Neuralgia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00506610. Target conditions include Postherpetic Neuralgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00506610 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Postherpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QUTENZA | Astellas Pharma | Approved | 85 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 33 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| RN624 + RN624 + Placebo | Pfizer | Phase 2 | 51 |
| pregabalin + pregabalin/PF-00489791 + Placebo | Pfizer | Phase 2 | 51 |
| PH-797804 + Placebo | Pfizer | Phase 2 | 51 |
| Placebo + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Approved | 84 |
| T-62 Dose 1 + T-62 Dose 2 | Pfizer | Phase 2 | 51 |
| HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |